Bristol Myers’ cell therapy chief Lynelle Hoch explains the reagent behind its autoimmune CAR-T pause and a puzzling MS trial ...
Basel-based Windward Bio filed for Nasdaq IPO as $WWB, advancing WIN378 and WIN027 from Kelun-Biotech, Harbour BioMed, and Qyuns for asthma, COPD, and eczema.
Al Sandrock is calling it quits as CEO of Voyager Therapeutics in the first quarter next year, but he will stay on the board.
Gilead pays $1.28B upfront to China's PepStar Therapeutics for oral IL-23 inhibitor HCXT-2001, targeting IBD and psoriasis, ...
The Swiss pharma is teaming up with Zymeworks, paying $55 million upfront for worldwide rights to a trispecific T cell ...
Biopharma M&A, licensing upfronts and VC all cooled in Q3, DealForma data show, while China’s share of pharma in-licensing kept climbing.
A key Republican congressman asked the Trump administration to restrict the stream of money into China’s biotech sector, threatening to squelch the dealmaking that’s become big ...
Alnylam & Regeneron's siRNA therapy brezosiran reduced mutant huntingtin protein 60-64% in 9 patients, spurring plans for a ...
Treasury’s draft outbound investment rules would sharply limit US deals for Chinese drug and biotech assets, opening a 45-day ...
AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response rates after 16 weeks by a statistically significant ...
Sanofi breaks ground on a Frankfurt insulin plant, FDA warns Baxter over cephalosporin contamination, and radiopharma players ...
Roche touts 88% Phase 3 success rate as it culls afimkibart’s AD trial and seven early assets ahead of giredestrant launch.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results